Association of prostate size and perioperative morbidity in thulium:YAG vapoenucleation of the prostate.
OBJECTIVE
To evaluate the association between perioperative morbidity and prostate size in patients with benign prostatic obstruction treated with thulium:YAG vapoenucleation of the prostate (ThuVEP).


METHODS
687 patients were prospectively analyzed. Prostate size was <40 ml in 196 (group A), 40-79 ml in 336 (group B) and ≥80 ml in 155 (group C) patients.


RESULTS
The mean prostate sizes were 27.94 ± 6.77, 54.38 ± 10.54 and 109.8 ± 28.31 ml for groups A, B and C, respectively (p < 0.001). Hemoglobin loss (g/dl) differed significantly among group A (1.09 ± 1.02), group B (1.28 ± 1.27) and group C (1.62 ± 1.49) (p < 0.001). The correlation between hemoglobin loss and prostate size was very weak in all patients (r = 0.13, p ≤ 0.001). Peak urinary flow rates and post-voiding residual urine improved significantly (p < 0.001) without differences among the groups. The incidence of complications was low and not different among the groups (acute urinary retention 8%, urinary tract infection 4.66%, secondary apical resection 2.91%, transfusion rate 2.03%).


CONCLUSIONS
Perioperative morbidity and micturition improvement are not associated with prostate size in ThuVEP.
Department of Urology, Asklepios Klinik Barmbek, Hamburg, Germany.
Christopher
C
Netsch
Christian
C
Tiburtius
Thorsten
T
Bach
Sophie
S
Knipper
Andreas J
AJ
Gross
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D015994:Incidence; D053685:Laser Therapy / Q000009:adverse effects*; D053844:Lasers, Solid-State; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D059035:Perioperative Period; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000601:surgery*; D053448:Prostatism / Q000209:etiology; D013932:Thulium; D016896:Treatment Outcome; D016055:Urinary Retention / Q000209:etiology; D014552:Urinary Tract Infections / Q000209:etiology; D014554:Urination
D013932:Thulium